Savient Pharmaceuticals, a US-based a speciality biopharmaceutical company, has named John Johnson chief executive officer; he will also serve as a member of the company's board of directors. He was most recently a senior vice-president at Lilly and president of Lilly Oncology Business Unit. Before that, Mr Johnson was CEO of ImClone Systems.
New CEO appointed at Savient
Savient Pharmaceuticals, a US-based a speciality biopharmaceutical company, has named John Johnson chief executive officer; he will also serve as a member of the company's board of directors. He was most recently a senior vice-president at Lilly and president of Lilly Oncology Business Unit. Before that, Mr Johnson was CEO of ImClone Systems.